NGS-based companion diagnostics

Fueling the future of precision oncology

Companion Diagnostics Development

The emergence of targeted therapies in oncology brings an increased need for companion diagnostic tests. Next-generation sequencing (NGS) is an ideal solution to transform the tumor profiling paradigm from a series of single gene tests to a multi-analyte approach to delivering precision oncology.

In partnership with leading pharmaceutical companies and the oncology community, Illumina is developing a universal oncology test system that aims to deliver a comprehensive set of the currently actionable and emerging biomarkers relevant to cancer drug development.

In the future, we plan to deliver regulatory compliant solutions to our pharma partners and ultimately to clinical testing laboratories by building on the Illumina MiSeqDx's status as the first FDA-regulated NGS instrument for use in in vitro diagnostic procedures. We will also leverage innovative library preparation, sequencing, and informatics solutions to enable powerful biological analysis, fueled by next-generation sequencing.

 

Illumina is bringing the power of NGS to clinical diagnostics. The CE-marked and FDA-regulated MiSeqDx System offers an ideal platform to perform these NGS-based assays. With its desktop footprint and easy-to-use interface, the MiSeqDx instrument delivers data output tailored to the needs of clinical labs. Already, two cystic fibrosis assays are in use by clinical laboratories. The MiSeqDx system and the Universal Kit provide a foundation upon which Illumina plans to build a menu of clinical solutions.

Illumina intends to expand the menu offered on the MiSeqDx through a development roadmap targeting applications in oncology.

 

Illumina is engaged with leaders of the oncology pharmaceutical industry in an effort to bring a universal oncology test system to market. Since 2014 Illumina has partnered with Amgen, Astra Zeneca, Merck Serono, and Sanofi to realize the value of precision oncology.

The Illumina Illumina Propel Certification Program is a collaborative service partnership. It is dedicated to ensuring you can obtain the high-quality data available for genetic analysis applications.

Illumina Propel certification provides a competitive advantage for service providers. It ensures that customers who use Illumina Propel services receive the industry-leading data quality and service they have come to expect from Illumina.

Interested in receiving newsletters, case studies, and information on genomics in drug development? Enter your email address.
How Genomics is Shaping the Future of Oncology
How Genomics is Shaping the Future of Oncology

Read an interview with John Leite, VP of Marketing for Illumina’s Oncology business.

Read Interview
Aiming for a Standard Method in Clinical Research
Aiming for a Standard Method in Clinical Research

Almac Diagnostics is using the TruSight Tumor 170 assay for comprehensive high-quality genomic content in one streamlined workflow.

Read Article
Immunotherapy Research and NGS
Immunotherapy Research and NGS

An overview of exciting new fields of immunotherapy research, and how NGS helps to move them forward.

View PDF
Removing Cancer's Veil: TruSight Tumor 170
Removing Cancer's Veil: TruSight Tumor 170

A new enrichment-based cancer research assay interrogates both DNA and RNA, detecting small variants, gene amplifications, gene fusions, and splice variants.

View Video
Service Partners and Programs
Service Partners and Programs

The Propel Certification Program is designed to promote high data quality and best practices at fee-for-service labs powered by Illumina.

Learn More